IKS's H-1B impact minimal; partnership with WWMG key to growth, says CFO Nithya Balasubramanian

Inventurus Knowledge Solutions (IKS Health), which provides healthcare enablement and revenue cycle management solutions to clients in the US, Canada, and Australia, says recent visa and regulatory developments have had little impact on its business.

Nithya Balasubramanian, Group CFO at IKS Health, said the company’s operations are largely unaffected by H-1B visa issues because of its hiring model. “Our business model is not to send people from India to the US. Whatever work we do in the US, we hire people locally.”

IKS Health operates with a mix of onshore and offshore teams--its commercial, customer success, and implementation teams are based in the US, while much of its technology and production workforce is in India.



She highlighted that the company’s partnership with Western Washington Medical Group (WWMG) is a key focus area. “The biggest goal is to establish a benchmark in how much transformation we can achieve when the platform is implemented at its fullest potential.”

The collaboration, she explained, is structured through a management services organisation (MSO), where physicians are also shareholders. “Doctors are shareholders of the MSO, so we benefit right alongside them,” she said. IKS has invested capital in the MSO to help expand its primary care network and drive operational efficiencies.

Also Read | Valuations reasonable, earnings stabilising: JPMorgan’s Sanjay Mookim expects near-term bounce, prefers consumer plays

According to Balasubramanian, IKS’s platform helps healthcare providers lower administrative costs and improve efficiency. “Typically, customers spend about 15% of their revenues on administrative tasks, and we deliver the same at 8% to 10%,” she said. “Over time, these physician groups also tend to realise an additional 5% uptick in revenue from productivity benefits.”

On growth expectations, she said the US remains IKS Health’s most important market, contributing about 99% of its revenue. “We firmly believe there is significant growth runway in the US. It’s blinders on - we’re focused on executing there,” she said.

Also Read | CGHS rate revision a positive step for cancer care, says HCG's BS Ajaikumar

The company aims to continue growing faster than the overall healthcare outsourcing market, which is expanding at around 12%. “We would want to grow several notches higher than that,” Balasubramanian said, adding that IKS expects its long-term margins to stay in the early-to-mid 30% range.

IKS Health, which has a market capitalisation of ₹26,541.51 crore, has seen its shares decline over 21% in the past year.

For the full interview, watch the accompanying video

Catch all the latest updates from the stock market hereRead about our editorial guidelines and ethics policy